当前位置:首页 - 行情中心 - 奥精医疗(688613) - 财务分析 - 利润表

奥精医疗

(688613)

  

流通市值:28.26亿  总市值:28.26亿
流通股本:1.37亿   总股本:1.37亿

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入104,064,611.2648,679,881.28223,736,817.67156,057,979.41
  营业收入104,064,611.2648,679,881.28223,736,817.67156,057,979.41
二、营业总成本108,570,712.6150,705,307.96233,158,629.73162,013,922.68
  营业成本38,210,298.8319,012,925.6270,121,192.2348,541,200.01
  税金及附加2,324,467.231,065,347.815,297,365.553,787,758.65
  销售费用24,417,035.288,653,896.1855,742,494.4637,648,031.3
  管理费用25,638,740.6912,625,188.8460,696,687.2243,062,612.17
  研发费用17,413,781.39,001,881.3139,249,862.3227,453,429.72
  财务费用566,389.28346,068.22,051,027.951,520,890.83
  其中:利息费用572,217.24-2,375,078.391,745,187.62
  其中:利息收入33,405.53-356,498.86-293,862.46
三、其他经营收益
  加:公允价值变动收益5,871,190.113,114,066.7113,054,629.269,867,996.01
  加:投资收益167,137.62-124,271.6439,774.48
  资产处置收益-92,981.99-88,678.97464,678.56154,087.33
  资产减值损失(新)---161,868.18-
  信用减值损失(新)-1,204,012.32-4,360,036.333,759,669.94
  其他收益873,534.16139,834.663,578,431.732,853,312.23
四、营业利润1,108,766.231,139,795.7211,998,367.2810,718,896.72
  加:营业外收入299,540.27-292,339.6130,351.03
  减:营业外支出1,103.561,103.553,150.312,686.18
五、利润总额1,407,202.941,138,692.1712,287,556.5810,746,561.57
  减:所得税费用231,552.09620,086.382,785,201.58150,793.13
六、净利润1,175,650.85518,605.89,502,35510,595,768.44
(一)按经营持续性分类
  持续经营净利润1,175,650.85518,605.89,502,35510,595,768.44
(二)按所有权归属分类
  归属于母公司股东的净利润2,754,582.861,410,974.6413,839,244.0913,940,614.52
  少数股东损益-1,578,932.01-892,368.84-4,336,889.09-3,344,846.08
  扣除非经常损益后的净利润-2,894,176.41-1,275,782.66-958,637.053,104,487.88
七、每股收益
  (一)基本每股收益0.020.010.10.1
  (二)稀释每股收益0.020.010.10.1
八、其他综合收益-562,316.5-389,686.31444,836.95770,228.41
  归属于母公司股东的其他综合收益-562,316.5-389,686.31444,836.95770,228.41
九、综合收益总额613,334.35128,919.499,947,191.9511,365,996.85
  归属于母公司股东的综合收益总额2,192,266.361,021,288.3314,284,081.0414,710,842.93
  归属于少数股东的综合收益总额-1,578,932.01-892,368.84-4,336,889.09-3,344,846.08
公告日期2026-08-292026-04-292026-04-292025-10-30
审计意见(境内)标准无保留意见
TOP↑